Seamless phase I/II design for novel anticancer agents with competing disease progression
From MaRDI portal
Publication:6627954
DOI10.1002/SIM.9080zbMATH Open1546.62097MaRDI QIDQ6627954
Author name not available (Why is that?), Shing M. Lee, Bin Cheng
Publication date: 29 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
Cites Work
- Title not available (Why is that?)
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- A nonidentifiability aspect of the problem of competing risks.
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Simple benchmark for complex dose finding studies
- Direct Parametric Inference for the Cumulative Incidence Function
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
- Bayesian optimal interval designs for phase I clinical trials
- A utility-based Bayesian phase I--II design for immunotherapy trials with progression-free survival end point
Related Items (1)
This page was built for publication: Seamless phase I/II design for novel anticancer agents with competing disease progression
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6627954)
